---
layout: post
title: TAF (tenofovir alafenamide) Professional Opinion - Support Letter
date: 2017-01-20 10:00:00
---

[![](/assets/images/taf-tenofovir-alafenamide-professional-opinion-support-letter.jpg)](https://jumpshare.com/v/r4w7U8U15dsj2MvuEGnY)

HBV is incurable but readily treatable with current all oral therapies. Providing the safest and most effective therapies to our patients is of the utmost importance. TAF is a significant step forward to provide this high safety margin.

Timothy M. Block, Ph.D and Robert G. Gish, MD comment on the use of TAF (tenofovir alafenamide), sold as Vemlidy (Gilead, Foster City, CA), with recent cases of denial at multiple sites in the U.S. by various insurance companies. 

[**>> Download Letter**](https://jumpshare.com/v/r4w7U8U15dsj2MvuEGnY)

